HCA Healthcare, Inc. (HCA)
NYSE: HCA · IEX Real-Time Price · USD
310.31
+5.20 (1.70%)
At close: Apr 22, 2024, 4:00 PM
313.99
+3.68 (1.19%)
After-hours: Apr 22, 2024, 7:47 PM EDT
HCA Healthcare Stock Forecast
Stock Price Forecast
The 20 analysts with 12-month price forecasts for HCA Healthcare stock have an average target of 316.1, with a low estimate of 265 and a high estimate of 359. The average target predicts an increase of 1.87% from the current stock price of 310.31.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for HCA Healthcare stock from 21 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 9 | 8 | 8 | 8 | 8 |
| Buy | 11 | 11 | 8 | 8 | 8 | 8 |
| Hold | 3 | 4 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 24 | 24 | 21 | 21 | 21 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Deutsche Bank | Deutsche Bank | Strong Buy Maintains $330 → $359 | Strong Buy | Maintains | $330 → $359 | +15.69% | Apr 12, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $335 | Buy | Reiterates | $335 | +7.96% | Apr 10, 2024 |
| Wells Fargo | Wells Fargo | Hold Maintains $303 → $315 | Hold | Maintains | $303 → $315 | +1.51% | Mar 28, 2024 |
| Barclays | Barclays | Buy Initiates $356 | Buy | Initiates | $356 | +14.72% | Mar 6, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $335 | Buy | Reiterates | $335 | +7.96% | Mar 5, 2024 |
Financial Forecast
Revenue This Year
69.78B
from 64.97B
Increased by 7.41%
Revenue Next Year
73.54B
from 69.78B
Increased by 5.38%
EPS This Year
20.79
from 18.97
Increased by 9.60%
EPS Next Year
23.29
from 20.79
Increased by 12.01%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 73.6B | 78.8B | 82.7B | 90.3B | 87.6B |
| Avg | 69.8B | 73.5B | 77.3B | 81.7B | 84.3B |
| Low | 66.7B | 69.9B | 73.3B | 76.1B | 81.8B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 13.2% | 12.9% | 12.4% | 16.7% | 7.2% |
| Avg | 7.4% | 5.4% | 5.2% | 5.7% | 3.1% |
| Low | 2.6% | 0.1% | -0.4% | -1.6% | 0.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 22.29 | 25.62 | 28.23 | 33.63 | 31.25 |
| Avg | 20.79 | 23.29 | 25.63 | 29.41 | 30.06 |
| Low | 19.70 | 21.95 | 23.21 | 26.84 | 29.16 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 17.5% | 23.2% | 21.2% | 31.2% | 6.3% |
| Avg | 9.6% | 12.0% | 10.1% | 14.7% | 2.2% |
| Low | 3.8% | 5.6% | -0.4% | 4.7% | -0.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.